{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:20:28Z","timestamp":1785154828300,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK123205"],"award-info":[{"award-number":["R01DK123205"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA048172"],"award-info":[{"award-number":["K01DA048172"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["IHS-1507-31640"],"award-info":[{"award-number":["IHS-1507-31640"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11606-024-08807-6","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:02:50Z","timestamp":1716472970000},"page":"2268-2276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The State of Hepatitis C Elimination from the Front Lines: A Qualitative Study of Provider-Perceived Gaps to Treatment Initiation"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2916-4175","authenticated-orcid":false,"given":"Christopher J.","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi N.","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Niederdeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpan","family":"Dharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Talal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey R.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Labossiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin F.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Wethington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"1","key":"8807_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12325-020-01535-3","volume":"38","author":"M Sulkowski","year":"2021","unstructured":"Sulkowski, M., et al., Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis\u00a0C. Adv Ther, 2021. 38(1): p. 423-440.","journal-title":"Adv Ther"},{"issue":"14","key":"8807_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","volume":"69","author":"AB Ryerson","year":"2020","unstructured":"Ryerson, A.B., et al., Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018. MMWR Morb Mortal Wkly Rep, 2020. 69(14): p. 399-404.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"8807_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/hep.27978","volume":"62","author":"BR Edlin","year":"2015","unstructured":"Edlin, B.R., et al., Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 2015. 62(5): p. 1353-63.","journal-title":"Hepatology"},{"issue":"5","key":"8807_CR4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik, J.M., et al., Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology, 2020. 72(5): p. 1605-1616.","journal-title":"Hepatology"},{"key":"8807_CR5","volume-title":"Combating Hepatitis B and C to Reach Elimination by 2030","author":"World Health Organization","year":"2016","unstructured":"World Health Organization, Combating Hepatitis B and C to Reach Elimination by 2030. 2016, World Health Organization: Geneva."},{"issue":"15","key":"8807_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2023.3692","volume":"329","author":"RL Fleurence","year":"2023","unstructured":"Fleurence, R.L. and F.S. Collins, A National Hepatitis C Elimination Program in the United States: A Historic Opportunity. Jama, 2023. 329(15): p. 1251-1252.","journal-title":"Jama"},{"issue":"1","key":"8807_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/apt.15291","volume":"50","author":"J Chhatwal","year":"2019","unstructured":"Chhatwal, J., et al., The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther, 2019. 50(1): p. 66-74.","journal-title":"Aliment Pharmacol Ther"},{"issue":"26","key":"8807_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.15585\/mmwr.mm7226a3","volume":"72","author":"C Wester","year":"2023","unstructured":"Wester, C., et al., Hepatitis C Virus Clearance Cascade - United States, 2013-2022. MMWR Morb Mortal Wkly Rep, 2023. 72(26): p. 716-720.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"8807_CR9","doi-asserted-by":"publisher","first-page":"e2327326","DOI":"10.1001\/jamanetworkopen.2023.27326","volume":"6","author":"SN Kapadia","year":"2023","unstructured":"Kapadia, S.N., et al., Hepatitis C Treatment Initiation Among US Medicaid Enrollees. JAMA Network Open, 2023. 6(8): p. e2327326-e2327326.","journal-title":"JAMA Network Open"},{"key":"8807_CR10","doi-asserted-by":"crossref","unstructured":"Kapadia, S.N., et al., The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination. Clinical Infectious Diseases, 2023. 2024 May 15;78(5):1235-1239.","DOI":"10.1093\/cid\/ciad503"},{"key":"8807_CR11","unstructured":"Services, U.S.D.o.H.a.H., Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021\u20132025). 2020: Washington, DC."},{"issue":"44","key":"8807_CR12","doi-asserted-by":"publisher","first-page":"7846","DOI":"10.3748\/wjg.v19.i44.7846","volume":"19","author":"M Zeremski","year":"2013","unstructured":"Zeremski, M., et al., Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol, 2013. 19(44): p. 7846-51.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"8807_CR13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","volume":"51","author":"AK Asher","year":"2016","unstructured":"Asher, A.K., et al., Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs. Substance Use & Misuse, 2016. 51(9): p. 1218-1223.","journal-title":"Substance Use & Misuse"},{"key":"8807_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102766","volume":"81","author":"T Goodyear","year":"2020","unstructured":"Goodyear, T., et al., \"Everybody living with a chronic disease is entitled to be cured\": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy, 2020. 81: p. 102766.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"8807_CR15","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/jvh.12987","volume":"25","author":"L Lafferty","year":"2018","unstructured":"Lafferty, L., et al., Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison. J Viral Hepat, 2018. 25(12): p. 1526-1532.","journal-title":"J Viral Hepat"},{"issue":"12","key":"8807_CR16","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1007\/s10620-016-4097-2","volume":"61","author":"M Thomson","year":"2016","unstructured":"Thomson, M., et al., Primary Care Physician Perspectives on Hepatitis C Management in the Era of Direct-Acting Antiviral Therapy. Dig Dis Sci, 2016. 61(12): p. 3460-3468.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"8807_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241615","volume":"15","author":"M Javanbakht","year":"2020","unstructured":"Javanbakht, M., R. Archer, and J. Klausner, Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system. PLoS One, 2020. 15(11): p. e0241615.","journal-title":"PLoS One"},{"key":"8807_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"A Amoako","year":"2021","unstructured":"Amoako, A., et al., Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. Int J Drug Policy, 2021. 96: p. 103247.","journal-title":"Int J Drug Policy"},{"key":"8807_CR19","doi-asserted-by":"crossref","unstructured":"Talal, A.H., et al., Hepatitis C Virus Elimination Programs in Louisiana and Washington: Importance of Screening and Surveillance Systems. Journal of Public Health Management and Practice. 2024 Mar-Apr 01;30(2):208-212.","DOI":"10.1097\/PHH.0000000000001808"},{"key":"8807_CR20","doi-asserted-by":"crossref","unstructured":"Andersen, R. and J.F. Newman, Societal and Individual Determinants of Medical Care Utilization in the United States. Milbank Q, 2005. 83(4).","DOI":"10.1111\/j.1468-0009.2005.00428.x"},{"issue":"1","key":"8807_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder, L.J., et al., Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementation Science, 2009. 4(1): p. 50.","journal-title":"Implementation Science"},{"key":"8807_CR22","doi-asserted-by":"crossref","unstructured":"Andersen, R. and J. Newman, Societal and Individual Determinants of Medical Care Utilization in the United States. 2005, Milbank Q.","DOI":"10.1111\/j.1468-0009.2005.00428.x"},{"key":"8807_CR23","doi-asserted-by":"crossref","unstructured":"Swain, J., A Hybrid Approach to Thematic Analysis in Qualitative Research: Using a Practical Example. Sage research methods, 2018.","DOI":"10.4135\/9781526435477"},{"issue":"2","key":"8807_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun, V. and V. Clarke, Using thematic analysis in psychology. Qualitative Research in Psychology, 2006. 3(2): p. 77-101.","journal-title":"Qualitative Research in Psychology"},{"key":"8807_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale, N.K., et al., Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol, 2013. 13: p. 117.","journal-title":"BMC Med Res Methodol"},{"key":"8807_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1037\/13620-004","volume-title":"APA handbook of research methods in psychology, Vol 2: Research designs: Quantitative, qualitative, neuropsychological, and biological","author":"V Braun","year":"2012","unstructured":"Braun, V. and V. Clarke, Thematic analysis, in APA handbook of research methods in psychology, Vol 2: Research designs: Quantitative, qualitative, neuropsychological, and biological. 2012, American Psychological Association: Washington, DC, US. p. 57-71."},{"key":"8807_CR27","unstructured":"Strauss, A. and J. Corbin, Basics of qualitative research: Techniques and procedures for developing grounded theory, 2nd ed. 1998, Sage Publications: Thousand Oaks, CA."},{"issue":"1","key":"8807_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder, L.J., et al., The updated Consolidated Framework for Implementation Research based on user feedback. Implementation Science, 2022. 17(1): p. 75.","journal-title":"Implementation Science"},{"issue":"8","key":"8807_CR29","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s10620-017-4608-9","volume":"62","author":"SS Rogal","year":"2017","unstructured":"Rogal, S.S., et al., Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence. Dig Dis Sci, 2017. 62(8): p. 1933-1943.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"8807_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s11606-022-07860-3","volume":"38","author":"SN Kapadia","year":"2023","unstructured":"Kapadia, S.N., et al., Specialist and Primary Care Treatment of Hepatitis C Infections in US Medicaid in 2018. Journal of General Internal Medicine, 2023. 38(5): p. 1323-1325.","journal-title":"Journal of General Internal Medicine"},{"key":"8807_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.drugpo.2019.06.002","volume":"72","author":"J Bryant","year":"2019","unstructured":"Bryant, J., et al., Making sense of \u2018side effects\u2019: Counterpublic health in the era of direct-acting antivirals. International Journal of Drug Policy, 2019. 72: p. 77-83.","journal-title":"International Journal of Drug Policy"},{"issue":"6","key":"8807_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2105\/AJPH.2020.305579","volume":"110","author":"MK Wolfe","year":"2020","unstructured":"Wolfe, M.K., N.C. McDonald, and G.M. Holmes, Transportation Barriers to Health Care in the United States: Findings From the National Health Interview Survey, 1997-2017. Am J Public Health, 2020. 110(6): p. 815-822.","journal-title":"Am J Public Health"},{"issue":"10","key":"8807_CR33","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jama.2019.22313","volume":"323","author":"CS Graham","year":"2020","unstructured":"Graham, C.S. and S. Trooskin, Universal Screening for Hepatitis C Virus Infection: A Step Toward Elimination. JAMA, 2020. 323(10): p. 936-937.","journal-title":"JAMA"},{"issue":"7","key":"8807_CR34","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cgh.2016.03.040","volume":"14","author":"V Lo Re 3rd","year":"2016","unstructured":"Lo Re, V., 3rd, et al., Disparities in Absolute Denial of Modern Hepatitis C Therapy\u00a0by\u00a0Type of Insurance. Clin Gastroenterol Hepatol, 2016. 14(7): p. 1035-43.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8807_CR35","unstructured":"Roundtable, N.V.H. and C.f.H.L.a.P.I.o.H.L. School. Hepatitis C: State of Medicaid Access: 2023 National Snapshot Report. 2023; Available from: https:\/\/stateofhepc.org\/2023-national-snapshot-report\/."},{"key":"8807_CR36","unstructured":"Roundtable, N.V.H. and C.f.H.L.a.P.I.o.H.L. School. Hepatitis C: State of Medicaid Access. 2023; Available from: https:\/\/stateofhepc.org\/."},{"issue":"8","key":"8807_CR37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jama.2019.21428","volume":"323","author":"JS Resneck Jr","year":"2020","unstructured":"Resneck, J.S., Jr., Refocusing Medication Prior Authorization on Its Intended Purpose. Jama, 2020. 323(8): p. 703-704.","journal-title":"Jama"},{"key":"8807_CR38","unstructured":"Bhattacharya, D., et al., Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2023 May 25:ciad319."},{"issue":"1","key":"8807_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jvh.13626","volume":"29","author":"DV Jugnarain","year":"2022","unstructured":"Jugnarain, D.V., et al., Role of peer support in a hepatitis C elimination programme. J Viral Hepat, 2022. 29(1): p. 43-51.","journal-title":"J Viral Hepat"},{"key":"8807_CR40","doi-asserted-by":"crossref","unstructured":"Talal, A.H., et al. Integrated Hepatitis C\u2013Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial. JAMA. 2024 Apr 23;331(16):1369-1378.","DOI":"10.1001\/jama.2024.2452"},{"issue":"7","key":"8807_CR41","doi-asserted-by":"publisher","first-page":"e2115523","DOI":"10.1001\/jamanetworkopen.2021.15523","volume":"4","author":"L Tran","year":"2021","unstructured":"Tran, L., et al., Association of the Extension for Community Healthcare Outcomes Project With Use of Direct-Acting Antiviral Treatment Among US Adults With Hepatitis C. JAMA Network Open, 2021. 4(7): p. e2115523-e2115523.","journal-title":"JAMA Network Open"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-08807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-024-08807-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-08807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:06:42Z","timestamp":1764266802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-024-08807-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["8807"],"URL":"https:\/\/doi.org\/10.1007\/s11606-024-08807-6","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"R.F. has received funds paid to his institution from Gilead Sciences, Inc., Abbvie, Merck & Co, Inc., and a consulting fee from Thera technologies. S.N.K. and A.R.L. have received funds paid to their institutions from Gilead Sciences, Inc. A.H.T. has received honoraria and funds to his institution from Gilead Sciences, and the latter from Merck and Co. and Abbott Laboratories. All other authors report no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"The statements in this work are solely the responsibility of the authors and do not necessarily represent the views of the National Institutes of Health, or PCORI, its Board of Governors or its Methodology Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}